Patient decision aid beneficial in papillary thyroid cancer

July 6, 2012
Patient decision aid beneficial in papillary thyroid cancer
Patients with early-stage papillary thyroid cancer may benefit from the use of a patient-directed computerized decision aid to provide medical knowledge and resolve decisional conflicts regarding the use of adjuvant radioactive iodine treatment, according to research published online July 2 in the Journal of Clinical Oncology.

(HealthDay) -- Patients with early-stage papillary thyroid cancer (PTC) may benefit from the use of a patient-directed computerized decision aid (DA) to provide medical knowledge and resolve decisional conflicts regarding the use of adjuvant radioactive iodine (RAI) treatment, according to research published online July 2 in the Journal of Clinical Oncology.

Anna M. Sawka, M.D., Ph.D., of the University Health Network and University of Toronto, and colleagues conducted a parallel, two-group, randomized, controlled trial involving 74 patients with early-stage PTC after (83.8 percent women; mean age, 45.8 years). Participants were randomly allocated to receive usual care with the use of a DA or usual care alone in a 1:1 ratio. Validated questionnaires were used to assess medical knowledge about PTC and RAI and decisional conflict.

The researchers found that, compared with the control group, participants in the DA group had significantly greater medical knowledge and significantly reduced decisional conflict. There was no significant difference between the groups for use of adjuvant RAI treatment (29.7 and 18.9 percent for DA group and control group, respectively; P = 0.278).

"In conclusion, a computerized patient-directed DA significantly improves medical knowledge and reduces decisional conflict in patients with early-stage PTC who are considering adjuvant RAI treatment," the authors write. "Our data also suggest that DAs may facilitate knowledge translation for decisions on cancer treatment that are subject to uncertainty of medical evidence."

Explore further: Study suggests obese patients have more advanced, aggressive papillary thyroid cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Study suggests obese patients have more advanced, aggressive papillary thyroid cancer

May 21, 2012
A review of medical records of patients treated at an academic tertiary care center suggests that obese patients present to their physicians with more advanced stage and more aggressive forms of papillary thyroid cancer (PTC), ...

BRAF addiction of thyroid cancers makes them therapeutically vulnerable

November 21, 2011
Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly ...

Financial hardship common among colon cancer patients

March 13, 2012
(HealthDay) -- Nearly 40 percent of patients undergoing adjuvant chemotherapy for stage III colon cancer experience financial hardship, even if they have health insurance coverage, according to research published online March ...

Adjuvant radiochemotherapy has lasting benefit in gastric cancer

May 18, 2012
(HealthDay) -- Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival (OS) and relapse-free ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.